TransCode's TTX-MC138 shows 71.4% stable disease in Phase 1a; no dose-limiting toxicities

Transcode Therapeutics, Inc.

10 of 14 efficacy-evaluable patients (71.4%) achieved stable disease as best overall response by investigator assessment; disease control was 57.1% at Cycle 3 Day 1 and 35.7% at Cycle 6 Day 1.
Durability: 6 of 14 patients progression-free at 3 months, 3 at 6, 9 and 12 months; three efficacy-evaluable patients remain progression-free at one year.
No dose-limiting toxicities at any dose including the highest evaluated 4.8 mg/kg; 98 doses administered as of the September 1, 2026 data cutoff; no treatment discontinuations.
Post-hoc Growth Modulation Index: 6 of 15 evaluable patients (40%) had GMI above 1.3, meaning at least 30% longer progression-free interval than their prior therapy.
Exploratory blood RNA-sequencing showed dose-dependent antitumor immune activation; TransCode is evaluating dose-expansion strategies in selected cancers and molecularly defined populations.

This headline and bullets were generated automatically by deepseek-v4.1-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.